Sleep Supplements for Insomnia: Matching by Subtype

Insomnia is not a single condition. The ICSD-3 classification distinguishes chronic insomnia disorder (symptoms 3+ nights per week for 3+ months), short-term insomnia (less than 3 months), and other insomnia disorders. Within chronic insomnia, clinical subtypes based on the primary complaint are practically important for supplement selection: sleep onset insomnia (difficulty falling asleep), sleep maintenance insomnia (frequent waking), early morning awakening, and non-restorative sleep (adequate duration but unrefreshing). Different supplements address different aspects of sleep physiology, and matching the compound to the presenting pattern improves outcome probability.

Sleep onset insomnia - lying awake with an active or anxious mind - is the most common pattern. It reflects excessive sympathetic nervous system activity, elevated cortisol, and insufficient inhibitory tone at sleep onset. Recommended compounds: L-Theanine (200-400mg) - increases alpha-wave EEG activity and reduces sympathetic arousal. Williams et al. (2016) showed significant reduction in stress-related sleep disruption. Suitable for anxiety-driven sleep onset difficulty. Magnesium glycinate (300-400mg elemental) - NMDA antagonism reduces neural excitability; GABA modulation provides inhibitory tone; cortisol normalisation reduces HPA-driven arousal. Glycine (3g) - reduces core body temperature through peripheral vasodilation, a key physiological trigger for sleep onset. Timing: 60-90 minutes before bed for all three.

Nocturnal awakening - waking once or multiple times during the night with difficulty returning to sleep - often reflects dysregulated cortisol (inappropriate cortisol rises during the night) or impaired slow-wave sleep architecture. Recommended compounds: Ashwagandha (300mg KSM-66 twice daily) - sustained HPA axis regulation; Langade et al. (2019) showed significant improvement in sleep continuity alongside sleep onset in chronic insomnia. Effects build over 8-10 weeks. Magnesium glycinate - Abbasi et al. (2012) showed improvements in sleep efficiency (proportion of time in bed spent sleeping) specifically - relevant to maintenance insomnia. Phosphatidylserine (100mg) - shown to reduce cortisol response; may help nocturnal cortisol dysregulation. Research is more limited than other compounds.

Early morning awakening (EMA) - waking 60-90 minutes before the intended or desired wake time and being unable to return to sleep - is the insomnia pattern most strongly associated with depression and elevated morning cortisol. If EMA is the primary complaint, clinical assessment for depression is appropriate as a first step. Where EMA is stress or lifestyle-related: Ashwagandha has the strongest rationale - its cortisol-blunting effects are most relevant to the elevated morning cortisol pattern underlying EMA. Magnesium via HPA axis regulation is also appropriate. Melatonin at low doses (0.3-1mg) taken closer to actual wake time can help reinforce the circadian sleep extension signal, though this requires careful timing and should be considered alongside CBT-I techniques for sleep restriction.

Non-restorative sleep - sleeping an apparently normal duration but waking unrefreshed - typically reflects poor sleep architecture: insufficient slow-wave sleep (SWS) or REM sleep despite adequate total sleep time. Causes include sleep apnoea (requires clinical investigation), alcohol (which suppresses REM), and stress-related cortisol disruption of sleep stage proportions. Supplements: Magnesium glycinate - evidence suggests magnesium may increase SWS proportion via NMDA antagonism. Glycine's REM-enhancing effect (Bannai et al., 2012) directly targets sleep architecture. Ashwagandha - Langade et al. (2019) found improvements in sleep quality scores (not just onset/maintenance) suggesting architecture benefit. Consider sleep apnoea screening before assuming supplement-addressable cause.

For chronic insomnia with multiple presenting features, a multi-mechanism approach is rationally superior to single compounds. An evidence-aligned stack: Magnesium glycinate (300-400mg elemental) + L-theanine (200-400mg) taken 60-90 minutes before bed addresses onset difficulty, neural excitability, and cortisol simultaneously. Ashwagandha (300mg KSM-66) taken twice daily (morning and evening) addresses sustained HPA axis dysregulation and maintenance/early-morning patterns over weeks. This combination covers the primary physiological pathways underlying most chronic insomnia - GABA/NMDA modulation, sympathetic arousal, HPA axis cortisol, and sleep architecture - without sedation or tolerance risk. CBT-I should be considered concurrently for chronic insomnia; supplements and behavioural intervention are complementary rather than competing approaches.